NCT03657472View on ClinicalTrials.gov

Bioequivalence Study of CJ-30061 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 19, 2016

Primary Completion Date

October 29, 2016

Study Completion Date

November 9, 2016

Conditions
HypertensionHyperlipidemia
Interventions
DRUG

CJ-30061

Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)

DRUG

Exforge® 5/160mg & Lipitor® 20mg

Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY